Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Agreement with Abcam

21st Dec 2006 09:49

Tepnel Life Sciences PLC21 December 2006 FOR IMMEDIATE RELEASE Tepnel Life Sciences plc ('Tepnel' or 'the Company') Tepnel signs international distribution agreement with world's largest online supplier of antibodies, Abcam Manchester, U.K, 21st December 2006 Tepnel Life Sciences PLC (AIM: TED), theUK-based international Molecular Diagnostics and Research Products & Servicesgroup, announced today that it has signed a global licensing agreement with theworld's largest online supplier of antibody products, Abcam (www.abcam.com) forthe distribution of Tepnel's Diaclone range of diagnostic and research products.The initial agreement includes an upfront payment to Tepnel and a guaranteedannual minimum in sales. The move significantly extends Tepnel's reach and willprovide immediate access to a broad range of customers from both academia andindustry. Dr Allan Brown, Managing Director of Tepnel Research Products & Servicescommented, "The agreement with Abcam is a significant one for Tepnel as ourDiaclone product range is already one of the world's leading sources ofimmunological products and with our new partnership, we will be able to furtherextend our market share. As the number one player in this market, Abcampossesses the awareness, reputation and know-how to help attain the marketpotential for Diaclone products." The distribution partnership with Abcam is an exclusive agreement for sales inJapan, Canada, and South America, co-exclusive (Tepnel and Abcam) in the US, andnon-exclusive elsewhere. Tepnel will continue to sell direct to customers inFrance, where the Diaclone division is headquartered. Established in 1986, the Diaclone division of Tepnel is fully dedicated to thedevelopment of immunological products designed for therapy, diagnostic andresearch applications. The vast Diaclone range includes products covering thefields of cytokines, and cytokine receptors, adhesion, apoptosis and CDantigens. All Diaclone products are manufactured according to ISO9001:2000guidelines. -End- For Further Information: Tepnel Life Sciences plcAllan Brown, Managing Director, Tepnel Research Products & Services0161 946 2200 De Facto CommunicationsRichard Anderson020 7861 3838 Notes to Editors About Tepnel Life Sciences plc Tepnel Life Sciences (AIM:TED) is a UK-based international life sciencesproducts and services group with two main divisions, Molecular Diagnostics andResearch Products & Services. The Company has laboratories, manufacturing andoperations in the USA, UK and France with 195 employees. TLS provides testkits, reagents and services to two highly synergistic markets, these beingMolecular Diagnostics and Biomedical Research. The company's strategy has beento identify high growth niche opportunities within these multi-billion poundmarkets. TLS focuses on these niche opportunities with internally developedproducts, patents, expertise and know-how as well as strategic acquisitions, todevelop a leadership position within these defined market segments. For further information, please visit: www.tepnel.com. This information is provided by RNS The company news service from the London Stock Exchange

Related Shares:

TED.LABC.L
FTSE 100 Latest
Value8,275.66
Change0.00